Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial




Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ, Airaksinen J

2011

Annals of Internal Medicine

10

155

10

660

667

9

0003-4819

DOIhttps://doi.org/10.1059/0003-4819-155-10-201111150-00004




Last updated on 2024-26-11 at 18:51